उत्पाद विवरण
Biceltis 440 mg injection is a targeted therapy designed for patients battling metastatic breast cancer and metastatic gastric cancer. This innovative medication is classified as a monoclonal antibody that specifically inhibits the HER2/neu receptor, a key player in the growth and spread of certain cancerous cells. By binding to these receptors, Biceltis effectively disrupts the proliferation of tumor cells, aiming to slow down disease progression and improve patient outcomes. While many patients tolerate this treatment well, it is important to be aware of potential side effects, which may include common reactions such as fatigue, nausea, and infusion-related symptoms. Regular monitoring and consultation with a healthcare provider are essential to manage any adverse effects and to evaluate treatment efficacy. As with any cancer therapy, discussing your medical history and any existing conditions with your doctor is crucial before starting treatment. Biceltis offers a promising option for those facing aggressive forms of cancer, bringing hope through its advanced mechanism of action.
Send Email 
जांच भेजें
जांच भेजें
एसएमएस भेजें
English
Spanish
French
German
Italian
Chinese (Simplified)
Japanese
Korean
Arabic
Portuguese